SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of
Federal Securities Laws by Certain Officers and Directors of CytRx Corporation
Levi & Korsinsky announces it has commenced an investigation of CytRx Corporation (NASDAQ:CYTR) (“CytRx”) concerning
possible violations of federal securities laws by the Company and/or certain of its officers and directors.
On July 11, 2016, CytRx announced the results of its Phase 3 clinical trial of aldoxorubicin, which did not show significant
improvement over other commonly used cancer drugs. The Company disclosed that nearly half of all patients in the Phase 3 trial were
excluded from the data because the study was interrupted by a partial clinical hold in November 2014. Following this announcement,
shares of CytRx were down more than 63% on intraday trading on July 12, 2016. To obtain additional information, go to:
http://zlk.9nl.com/cytr-cytrx
or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by
telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The
firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors
throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar
outcomes.
Levi & Korsinsky, LLP
Eduard Korsinsky, Esq., 212-363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20160718006338/en/